<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR2">
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Alharbi</surname>
    <given-names>NK</given-names>
   </name>
   <name>
    <surname>Padron-Regalado</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Thompson</surname>
    <given-names>CP</given-names>
   </name>
   <name>
    <surname>Kupke</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Wells</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Sloan</surname>
    <given-names>MA</given-names>
   </name>
   <name>
    <surname>Grehan</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Temperton</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Lambe</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Warimwe</surname>
    <given-names>G</given-names>
   </name>
   <name>
    <surname>Becker</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Hill</surname>
    <given-names>AVS</given-names>
   </name>
   <name>
    <surname>Gilbert</surname>
    <given-names>SC</given-names>
   </name>
  </person-group>
  <article-title>ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice</article-title>
  <source>Vaccine</source>
  <year>2017</year>
  <volume>35</volume>
  <issue>30</issue>
  <fpage>3780</fpage>
  <lpage>3788</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.05.032</pub-id>
  <pub-id pub-id-type="pmid">28579232</pub-id>
 </element-citation>
</ref>
